About
Our Story
Leadership
Research Partners
Our Science
ImmuX Technology
FusionX Technology
IME Cell Technology
R&D Pipeline
Publications
Media
Careers
Contact
About
Our Story
Leadership
Research Partners
Our Science
ImmuX Technology
FusionX Technology
IME Cell Technology
R&D Pipeline
Publications
Media
Careers
Contact
中文
English
Our Story
2021.H1
• Seed stage funding done • Key members onboard
2021.H1
• Seed stage funding done • Key members onboard
2021.H2
• 1st project CD-001 kickoff • Early research began • Patent assignments initiated
2021.H2
• 1st project CD-001 kickoff • Early research began • Patent assignments initiated
2022.H1
• Pre-A funding started • CD-202 IIT initiated • 2nd project CD-002 kickoff • CD-001 CMC started
2022.H1
• Pre-A funding started • CD-202 IIT initiated • 2nd project CD-002 kickoff • CD-001 CMC started
2022.H2
• Core teams assembled • Suzhou R&D facilities operating • CD-001 Pharmacology initiated
2022.H2
• Core teams assembled • Suzhou R&D facilities operating • CD-001 Pharmacology initiated
2023.H1
• CD-203 IIT initiated • CD-001 CMC Tox batch ready
2023.H1
• CD-203 IIT initiated • CD-001 CMC Tox batch ready
2023.H2
• Pre-series A funding • CD-001 Tox study initiated • CD-001 CMC clinical batch ready
2023.H2
• Pre-series A funding • CD-001 Tox study initiated • CD-001 CMC clinical batch ready
2024.H1
• CD-202 AACR poster presentation • CD-001 IND nonclinical studies • CD-001 IND application started
2024.H1
• CD-202 AACR poster presentation • CD-001 IND nonclinical studies • CD-001 IND application started
2024.H2
• Pre-series A+ funding • CD-001 FPI goal • New series funding goal
2024.H2
• Pre-series A+ funding • CD-001 FPI goal • New series funding goal
Company Highlights
Breakthrough in Immunotherapy
• Target specific cells to tune immune responses precisely • Optimize immunomodulators to achieve better efficacy • Provide additional immunotherapy strategy with a huge market
Next Generation Immunotherapy
•A highly productive, clinical-stage, biotech company founded in 2021 •Developing drugs through precisely calibrating immune system •Research and development (R&D) cover a broad spectrum in immunotherapy, including oncology, viral infections, and autoimmune diseases
Precision Immunotherapy Platform
• Proprietary Bispecific Fusion Protein (BsFP) with three key technologies • Unique cell modification technology (IME Cell) for clinical feasibility exploration • 1st program (CD-001) FIH ready to start within next 3 months
Mission
Developing immunotherapies through precisely calibrating immune system
